Safety Concerns with HPV Vaccines Continue to Linger: Are Current Vaccine Pharmacovigilance Practices Sufficient?

Drug Safety

Volumn 40, Issue 12, 2017, Pages 1167-1170

  Chandler, Rebecca E ^a  

^a UPPSALA MONITORING CENTRE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ABDOMINAL DISCOMFORT; AUTONOMIC NEUROPATHY; CEREBROVASCULAR ACCIDENT; CHRONIC FATIGUE SYNDROME; CLINICAL OUTCOME; COGNITIVE DEFECT; COLOMBIA; COMPLEX REGIONAL PAIN SYNDROME; DIZZINESS; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DYSAUTONOMIA; EPIDEMIOLOGICAL DATA; FAINTNESS; FATIGUE; HEADACHE; HUMAN; ITALY; JAPAN; LIMB DISEASE; LIMB WEAKNESS; MEXICO; MOTOR DYSFUNCTION; NETHERLANDS; NOTE; ORTHOSTATIC INTOLERANCE; PAIN; PATIENT ADVOCACY; PLETHYSMOGRAPHY; POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RASH; SENSORY DYSFUNCTION; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; SLEEP DISORDER; VACCINATION; PAPILLOMAVIRUS INFECTION;

HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PHARMACOVIGILANCE; VACCINATION;

EID: 85028614779     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-017-0593-3     Document Type: Note

References (29)

1. Global Advisory Committee on Vaccine Safety (GACVS) and World Health Organization Secretariat. Global safety of vaccines: strengthening systems for monitoring, management and the role of GACVS. Expert Rev Vaccines. 2009;8(6):705–16.
2. Bonhoeffer J, Kohl K, Chen R, Duclos P, Heijbel H, Heininger U, Jefferson T, Loupi E. The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine. 2002;21(3–4):298–302.
3. Tozzi AE, Asturias EJ, Balakrishnan MR, Halsey NA, Law B, Zuber PL. Assessment of causality of individual adverse events following immunization (AEFI): a WHO tool for global use. Vaccine. 2013;31(44):5041–6.
4. Guideline on good pharmacovigilance practices (GVP): Product‐ or population‐specific considerations I: vaccines for prophylaxis against infectious diseases, 9 Dec 2013. EMA/488220/2012.
5. Ozawa K, Hineno A, Kinoshita T, Ishihara S, Ikeda SI. Suspected adverse effects after human papillomavirus vaccination: a temporal relationship between vaccine administration and the appearance of symptoms in Japan. Drug Saf. 2017. doi:10.1007/s40264-017-0574-6.
6. Blitshteyn S. Postural tachycardia syndrome following human papilloma vaccination. Eur J Neurol. 2014;21(1):135–9.
7. Kinoshita T, Abe R-T, Hineno A, Tsunekawa K, Nakane S, Ikeda S. Peripheral sympathetic nerve dysfunction in adolescent Japanese girls following immunization with the human papillomavirus vaccine. Intern Med. 2014;53:2185–200.
8. Lareb. Long-lasting adverse events following immunization with Cervarix®. 2015. http://databankws.lareb.nl/Downloads/Lareb_rapport_HPV_dec15_03.pdf.
9. Brinth LS, Pors K, Theibel AC, Mehlsen J. Orthostatic intolerance and postural tachycardia syndrome as suspected adverse effects of vaccination against human papilloma virus. Vaccine. 2015;33(22):2602–5.
10. Palmieri B, Poddighe D, Vadalà M, Laurino C, Carnovale C, Clementi E. Severe somatoform and dysautonomic syndromes after HPV vaccination: case series and review of literature. Immunol Res. 2017;65:117–9.
11. Martínez-Lavín M. Fibromyalgia-like illness in 2 girls after human papillomavirus vaccination. J Clin Rheumatol. 2014;20(7):392–3.
12. Pompilio M. Motor and sensory clinical findings in girls vaccinated against the human papillomavirus from Carmen de Bolivar, Colombia. https://pompiliomartinez.wordpress.com/2016/03/04/motor-and-sensory-clinical-findings-in-girls-vaccinated-against-the-human-papillomavirus-from-carmen-de-bolivar-colombia/.
13. HPV vaccines: EMA confirms evidence does not support that they cause CRPS or POTS. EMA/749763/2015. 2015. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/HPV_vaccines_20/Opinion_provided_by_Committee_for_Medicinal_Products_for_Human_Use/WC500196773.pdf.
14. Skufca J, Ollgren J, Ruokokoski E, Lyytikäinen O, Nohynek H. Incidence rates of Guillain Barré (GBS), chronic fatigue/systemic exertion intolerance disease (CFS/SEID) and postural orthostatic tachycardia syndrome (POTS) prior to introduction to human papilloma virus (HPV) vaccination among adolescent girls in Finland, 2002–2012. Papillomavirus Res. 2017;3:91–6.
15. Donegan K, Beau-Lejdstrom R, King B, Seabroke S, Thomson A, Bryan P. Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK. Vaccine. 2013;31(43):4961–7.
16. Feiring B, Laake I, Bakken IJ, Greve-Isdahl M, Wyller VB, Håberg SE, Magnus P, Trogstad L. HPV vaccination and risk of chronic fatigue syndrome/myalgic encephalomyelitis: a nationwide register-based study from Norway. Vaccine. 2017;35(33):4203–12.
17. Sentinel CBER/PRISM surveillance plan. A safety study of gardasil 9 in Prism/Sentinel using sequential analysis. https://www.sentinelinitiative.org/sites/default/files/PRISM/Sentinel_PRISM_HPV9-Sequential-Analysis_Surveillance-Plan.pdf.
18. Butts BN, Fischer PR, Mack KJ. Human papillomavirus vaccine and postural orthostatic tachycardia syndrome: a review of current literature. J Child Neurol. 2017. doi:10.1177/0883073817718731.
19. Børne vaccinations programmet. Årsrapport 2016. http://www.ssi.dk//media/Indhold/DK%20-%20dansk/Vaccination/Boernevaccination/BoernevaccProgramAarsrap2016_26apr17.ashx.
20. HPV vaccine uptake in Ireland: 2015/2016. https://www.hpsc.ie/a-z/vaccinepreventable/vaccination/immunisationuptakestatistics/hpvimmunisationuptakestatistics/File,16039,en.pdf.
21. Chandler RE, Juhlin K, Fransson J, Caster O, Edwards IR, Norén GN. Current safety concerns with human papillomavirus vaccine: a cluster analysis of reports in VigiBase®. Drug Saf. 2017;40(1):81–90.
22. Poland GA, Ovsyannikova IG, Jacobson RM. Adversomics: the emerging field of vaccine adverse event immunogenetics. Pediatr Infect Dis J. 2009;28(5):431–2.
23. Bomfim IL, Lamb F, Fink K, Szakács A, Silveira A, Franzén L, Azhary V, Maeurer M, Feltelius N, Darin N, Hallböök T, Arnheim-Dahlström L, Kockum I, Olsson T. The immunogenetics of narcolepsy associated with A(H1N1)pdm09 vaccination (Pandemrix) supports a potent gene–environment interaction. Genes Immun. 2017;18:75–81.
24. Mølbak K, Hansen ND, Valentiner-Branth P. Pre-vaccination care-seeking in females reporting severe adverse reactions to HPV vaccine. A registry based case-control study. PLoS One. 2016;11(9):e0162520.
25. Hendrickson JE. Human papilloma virus vaccination and dysautonomia: considerations for autoantibody testing and HLA typing. Vaccine. 2016;34(38):4468.
26. Blitshteyn S, Brook J. Postural tachycardia syndrome (POTS) with anti-NMDA receptor antibodies after human papillomavirus vaccination. Immunol Res. 2017;65(1):282–4.
27. Ruzieh M, Batizy L, Dasa O, Oostra C, Grubb B. The role of autoantibodies in the syndromes of orthostatic intolerance: a systematic review. Scand Cardiovasc J. 2017. doi:10.1080/14017431.2017.1355068.
28. Kohr D, Singh P, Tschernatsch M, Kaps M, Pouokam E, Diener M, et al. Autoimmunity against the β2 adrenergic receptor and muscarinic-2 receptor in complex regional pain syndrome. Pain. 2011;152(12):2690–700.
29. Loebel M, Grabowski P, Heidecke H, Bauer S, Hanitsch LG, Wittke K, et al. Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with chronic fatigue syndrome. Brain Behav Immun. 2016;52:32–9.